Author: Steve Kopczak

LitAlert ~~ GeneLit.com

    • Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
    • Li J, Li Q, Zhang L, Zhang S, Dai Y.
    • Biomed Pharmacother. 2022 Nov 18;157:114028. doi: 10.1016/j.biopha.2022.114028. Epub ahead of print.

    • Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations.
    • Wu MS, Goldberg H.
    • Cancer Manag Res. 2022 Nov 15;14:3159-3174. doi: 10.2147/CMAR.S353411.

    • Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer.
    • Astiazaran-Symonds E, Graham C, Kim J, Tucker MA, Ingvar C, Helgadottir H, Pastorino L, van Doorn R, Sampson JN, Zhu B, Bruno W, Queirolo P, Fornarini G, Sciallero S, Carter B, Hicks B, Hutchinson A, Jones K, Stewart DR, Chanock SJ, Freedman ND, Landi MT, Höiom V, Puig S, Gruis N, Yang XR, Ghiorzo P, Goldstein AM.
    • JCO Precis Oncol. 2022 Nov;6:e2200145. doi: 10.1200/PO.22.00145.

    • LitAlert ~~ GeneLit.com

    • [Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
    • Tanaka Y, Oota R, Takagi Y, Kodama W, Nishimura K, Hamasaki T, Fukino S, Suo K.
    • Gan To Kagaku Ryoho. 2022 Nov;49(11):1271-1273. Japanese.
    • Case report. [Article in Japanese]

    • Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer.
    • Astiazaran-Symonds E, Graham C, Kim J, Tucker MA, Ingvar C, Helgadottir H, Pastorino L, van Doorn R, Sampson JN, Zhu B, Bruno W, Queirolo P, Fornarini G, Sciallero S, Carter B, Hicks B, Hutchinson A, Jones K, Stewart DR, Chanock SJ, Freedman ND, Landi MT, Höiom V, Puig S, Gruis N, Yang XR, Ghiorzo P, Goldstein AM.
    • JCO Precis Oncol. 2022 Nov;6:e2200145. doi: 10.1200/PO.22.00145.

    • LitAlert ~~ GeneLit.com

    • Investigating Psychological Impact after Receiving Genetic Risk Results—A Survey of Participants in a Population Genomic Screening Program.
    • Zayac McCormick CZ, Dilzell Yu K, Johns A, Campbell-Salome G, Hallquist MLG, Sturm AC, Buchanan AH.
    • J Pers Med. 2022 Nov 22;12(12):1943. doi: 10.3390/jpm12121943.

    • The Prospective Lynch Syndrome Database: background, design, main results and complete MySQL code.
    • Møller P.
    • Hered Cancer Clin Pract. 2022 Nov 21;20(1):37. doi: 10.1186/s13053-022-00243-z.

    • Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
    • Li J, Li Q, Zhang L, Zhang S, Dai Y.
    • Biomed Pharmacother. 2022 Nov 18;157:114028. doi: 10.1016/j.biopha.2022.114028. Epub ahead of print.

    • Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations.
    • Wu MS, Goldberg H.
    • Cancer Manag Res. 2022 Nov 15;14:3159-3174. doi: 10.2147/CMAR.S353411.

    • [Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
    • Tanaka Y, Oota R, Takagi Y, Kodama W, Nishimura K, Hamasaki T, Fukino S, Suo K.
    • Gan To Kagaku Ryoho. 2022 Nov;49(11):1271-1273. Japanese.
    • Case report. [Article in Japanese]

    • Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer.
    • Astiazaran-Symonds E, Graham C, Kim J, Tucker MA, Ingvar C, Helgadottir H, Pastorino L, van Doorn R, Sampson JN, Zhu B, Bruno W, Queirolo P, Fornarini G, Sciallero S, Carter B, Hicks B, Hutchinson A, Jones K, Stewart DR, Chanock SJ, Freedman ND, Landi MT, Höiom V, Puig S, Gruis N, Yang XR, Ghiorzo P, Goldstein AM.
    • JCO Precis Oncol. 2022 Nov;6:e2200145. doi: 10.1200/PO.22.00145.

    • Relationship between Baseline [18F]FDG PET/CT Semiquantitative Parameters and BRCA Mutational Status and Their Prognostic Role in Patients with Invasive Ductal Breast Carcinoma.
    • Dondi F, Albano D, Bellini P, Camoni L, Treglia G, Bertagna F.
    • Tomography. 2022 Oct 27;8(6):2662-2675. doi: 10.3390/tomography8060222.

    • Pancreatic Cancer Screening Appears Safe, Effective for High-Risk Patients.
    • Crist C.
    • Medscape Oncology. 2022 Oct 26.

    • Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
    • Yanaihara N, Yoshino Y, Noguchi D, Tabata J, Takenaka M, Iida Y, Saito M, Yanagida S, Iwamoto M, Kiyokawa T, Chiba N, Okamoto A.
    • Gynecol Oncol. 2022 Nov 17;168:83-91. doi: 10.1016/j.ygyno.2022.11.006. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Editorial: Prostate Cancer Genomics: Application at Different Stages of a Patient's Journey.
    • Poon DM, Azad A, Castro E, Kanesvaran R, Sartor O.
    • Front Oncol. 2022 Nov 21;12:1101678. doi: 10.3389/fonc.2022.1101678.

    • UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.
    • Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda RM, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Marc Tischkowitz M, On behalf of Consensus meeting attendees, Lalloo F.
    • J Med Genet. 2022 Nov 21:jmg-2022-108898. doi: 10.1136/jmg-2022-108898. Epub ahead of print.

    • In silico and structure-based assessment to classify VUS identified in the a-helical domain of BRCA2.
    • Khan MA, Varma AK.
    • J Biomol Struct Dyn. 2022 Nov 20:1-11. doi: 10.1080/07391102.2022.2148127. Epub ahead of print.

    • Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
    • Yanaihara N, Yoshino Y, Noguchi D, Tabata J, Takenaka M, Iida Y, Saito M, Yanagida S, Iwamoto M, Kiyokawa T, Chiba N, Okamoto A.
    • Gynecol Oncol. 2022 Nov 17;168:83-91. doi: 10.1016/j.ygyno.2022.11.006. Epub ahead of print.

    • Dose Adjustment of Poly (ADP-Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment.
    • Zhao D, Long X, Wang J.
    • Drug Des Devel Ther. 2022 Nov 14;16:3947-3955. doi: 10.2147/DDDT.S387920.

    • Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascites.
    • Miceska S, Škof E, Novakovic S, Stegel V, Jericevic A, Grcar Kuzmanov B, Smrkolj Š, Cvjeticanin B, Bebar S, Globocnik Kukovica M, Kloboves-Prevodnik V.
    • Cancer Cytopathol. 2022 Nov 18. doi: 10.1002/cncy.22664. Epub ahead of print.

    • 3D CRISPR Screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction.
    • Zhang H, Gao H, Gu Y, John A, Wei L, Huang M, Yu J, Adeosun A, Weinshilboum R, Wang L.
    • Front Oncol. 2022 Nov 14;12:999302. doi: 10.3389/fonc.2022.999302.

    • Mastectomy with one-stage or two-stage reconstruction in breast cancer: analysis of early outcomes and patient's satisfaction.
    • Angela G, Alessandro P, Alessia T, Michele M, Rossella E, Marco M, Michele T, Giuseppe Massimiliano L, Walter L, Elisabetta P, Paolo PF, Ilaria SL, Giuseppe G, Mario T.
    • Updates Surg. 2022 Nov 19. doi: 10.1007/s13304-022-01416-0. Epub ahead of print.